Transcenta Holding Limited
HKEX:6628.HK
Overview | Financials
Company Name | Transcenta Holding Limited |
Symbol | 6628.HK |
Currency | HKD |
Price | 0.89 |
Market Cap | 392,050,411 |
Dividend Yield | 0% |
52-week-range | 0.87 - 4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Xueming Qian Ph.D. |
Website | https://www.transcenta.com |
An error occurred while fetching data.
About Transcenta Holding Limited
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD